Study on preoperative concurrent chemoradiotherapy with S-1 in oral cancer (Phase II study)

Study on preoperative concurrent chemoradiotherapy with S-1 in oral cancer (Phase II study) - Study on preoperative concurrent chemoradiotherapy with S-1 in oral cancer (Phase II study)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002329

Enrollment

Registered

2009-08-18

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral cancer

Interventions

The total 40Gy of irradiation is delivered to both primary site and metastasized neck region. Chemotherapy regimen consisted of 5-day S-1 consecutive administration, followed by 2-day rest for 4 week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The cases with advanced oral cancer, the cases with no previous treatment

Exclusion criteria

Exclusion criteria: The cases who have simultaneously another cancer, the cases who have severe complication in their body

Design outcomes

Primary

Measure	Time frame
Tumor reduction 4 weeks after chemoradiotherapy	—

Secondary

Measure	Time frame
Adverse events on chemoradiotherapy	—

Countries

Japan

Contacts

Public ContactHideki Nakayama

Graduate School, Kumamoto university Oral & Maxillofacial Surgery

hinakaya@fc.kuh.kumamoto-u.ac.jp096-373-5288

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026